Alkeon Capital Management
ALXN

Alkeon Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Alkeon Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-500,000
Closed -$70.1M – 105
2017
Q3 		$70.1M Buy
+500,000
New +$67.9M 0.5% 54
2017
Q1 		– Sell
-404,202
Closed -$49.5M – 69
2016
Q4 		$49.5M Sell
404,202
-26,043
-6% -$3.19M 0.98% 43
2016
Q3 		$52.7M Sell
430,245
-650
-0.2% -$83.7K 0.99% 37
2016
Q2 		$53.6M Buy
430,895
+355
+0.1% +$50.4K 1.03% 38
2016
Q1 		$59.9M Buy
430,540
+670
+0.2% +$98.4K 1.24% 33
2015
Q4 		$82M Sell
429,870
-257,000
-37% -$44.9M 1.66% 26
2015
Q3 		$113M Hold
686,870
– – 2.36% 17
2015
Q2 		$124M Hold
686,870
– – 2.42% 15
2015
Q1 		$119M Sell
686,870
-43,700
-6% -$7.91M 2.27% 20
2014
Q4 		$135M Sell
730,570
-248,000
-25% -$46M 2.64% 15
2014
Q3 		$162M Hold
978,570
– – 3.22% 7
2014
Q2 		$153M Buy
978,570
+43,940
+5% +$6.94M 2.79% 8
2014
Q1 		$142M Buy
934,630
+70,000
+8% +$11.1M 2.4% 14
2013
Q4 		$115M Buy
864,630
+133,000
+18% +$16M 1.94% 25
2013
Q3 		$85M Buy
731,630
+106,630
+17% +$11.7M 1.66% 27
2013
Q2 		$57.6M Buy
+625,000
New +$60.2M 1.29% 32

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Alkeon Capital Management's ALXN Position: Q4 2017 in Review

Alkeon Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 500,000 shares — an estimated $70.1M sold.

Alkeon Capital Management first reported a position in ALXN in Q2 2013 and held it in 16 quarters. The position peaked at $162M in Q3 2014. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Alkeon Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Alkeon Capital Management sold 500,000 Alexion Pharmaceuticals shares in Q4 2017, an estimated $70.1M.
  • Alkeon Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Alkeon Capital Management's Alexion Pharmaceuticals position peaked at $162M in Q3 2014.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Alkeon Capital Management's 13F filing for Q4 2017, filed 15 Feb 2018.